UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of Registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File No.) |
| (IRS Employer Identification No.) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
N/A
(Former name or former address if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14c)) |
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 2, 2022, CEL-SCI Corporation appointed Gail K. Naughton, Ph.D. to its Board of Directors.
Dr. Gail K Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world’s first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch.
Dr. Naughton founded Histogen Inc. (NASDAQ:HSTO) in 2007 and holds more than 125 U.S. and foreign patents and has been extensively published in the field.
Dr. Naughton served as Dean of the College of Business Administration at San Diego State University from 2002 until 2011, where she helped to make SDSU the first US campus to establish a Ph.D./MBA in life sciences.
In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering and regenerative medicine.
Dr. Naughton received her Ph.D. and M.S. from NYU Medical Center, and an MBA from UCLA. She currently sits on the Board of directors of Therapeutics MD (NASDAQ: TXMD) and is the Chair of the Board of the La Jolla Institute for Immunology.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 8, 2022 | CEL-SCI CORPORATION | ||
| By: | /s/ Patricia Prichep | ||
|
| Patricia B. Prichep | |
| Senior Vice President of Operations | |||
| 3 |
Cover |
Aug. 02, 2022 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | CEL-SCI CORPORATION |
| Entity Central Index Key | 0000725363 |
| Document Type | 8-K |
| Amendment Flag | false |
| Entity Emerging Growth Company | false |
| Document Period End Date | Aug. 02, 2022 |
| Entity Incorporation State Country Code | CO |
| Entity Tax Identification Number | 84-0916344 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Entity File Number | 001-11889 |
| Entity Address City Or Town | Vienna |
| Entity Address State Or Province | VA |
| Entity Address Postal Zip Code | 22182 |
| City Area Code | 703 |
| Local Phone Number | 506-9460 |
| Security 12b Title | Common Stock |
| Trading Symbol | CVM |
| Security Exchange Name | NYSEAMER |
| Entity Address Address Line 1 | 8229 Boone Boulevard, Suite 802 |